Volume 152, Issue 1, Pages (January 2019)

Slides:

Advertisements

Similar presentations

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Volume 144, Issue 1, Pages (January 2017)

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Volume 376, Issue 9747, Pages (October 2010)

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Volume 16, Issue 8, Pages (August 2015)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 150, Issue 3, Pages (September 2018)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Table 2. Progression-Free Survival

Volume 152, Issue 1, Pages (January 2019)

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Volume 148, Issue 1, Pages (January 2018)

The development and use of vascular targeted therapy in ovarian cancer

Volume 145, Issue 2, Pages (May 2017)

Volume 387, Issue 10023, Pages (March 2016)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage.

Volume 152, Issue 1, Pages (January 2019)

Comparison of Conservative Treatment and Thymectomy on Myasthenia Gravis Outcome Emanuela Taioli, MD, PhD, Philip Kent Paschal, Bian Liu, PhD, Andrew.

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for.

Volume 152, Issue 1, Pages (January 2019)

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Volume 376, Issue 9747, Pages (October 2010)

Volume 151, Issue 1, Pages (October 2018)

Volume 130, Issue 1, Pages (July 2013)

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Volume 153, Issue 3, Pages (June 2019)

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 152, Issue 1, Pages 53-60 (January 2019) Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer Antonio González Martín, Amit M. Oza, Andrew C. Embleton, Jacobus Pfisterer, Jonathan A. Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Monique A. Bertrand, Philip Beale, Andrés Cervantes, Emma Kent, Richard S. Kaplan, Mahesh K.B. Parmar, Nana Scotto, Timothy J. Perren Gynecologic Oncology Volume 152, Issue 1, Pages 53-60 (January 2019) DOI: 10.1016/j.ygyno.2018.08.036 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Distribution of the study population (treatment arms pooled) according to residual disease and stage. Subgroups in shaded boxes correspond to the Medical Research Council-defined ‘high-risk’ subgroup. NOS, not otherwise specified. Gynecologic Oncology 2019 152, 53-60DOI: (10.1016/j.ygyno.2018.08.036) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Subgroup analyses of efficacy by stage. (A) progression-free survival; (B) overall survival. CI, confidence interval; HR, hazard ratio. Gynecologic Oncology 2019 152, 53-60DOI: (10.1016/j.ygyno.2018.08.036) Copyright © 2018 The Authors Terms and Conditions

Fig. 3 Summary of PFS and OS in patients with stage IIIB–IV disease. CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival. Gynecologic Oncology 2019 152, 53-60DOI: (10.1016/j.ygyno.2018.08.036) Copyright © 2018 The Authors Terms and Conditions

Fig. 4 Subgroup analyses of efficacy: (A) PFS and (B) OS; (i) Stage IIIB–IV (n = 1160); (ii) Stage IIIB–IV with no visible residual disease (n = 411); (iii) Stage IIIB–IV with visible residual disease (n = 749). CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival. Gynecologic Oncology 2019 152, 53-60DOI: (10.1016/j.ygyno.2018.08.036) Copyright © 2018 The Authors Terms and Conditions

Fig. 5 Subgroup analyses by stage and residual disease status in the stage III/IV subgroup. CI, confidence interval; HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival. Gynecologic Oncology 2019 152, 53-60DOI: (10.1016/j.ygyno.2018.08.036) Copyright © 2018 The Authors Terms and Conditions